Siemens Healthineers: Diagnostics Drag Meets Technical Recovery Ahead of Q3
Published on 07/27/2026 at 17:22 | Redaktion boerse-global.de
Siemens Healthineers shares climbed 2.4% to €35.63 on Monday, extending a rebound that has been building for weeks. The medical technology group has now recaptured its 50-day moving average, a milestone it first crossed on July 24 that technicians view as a potential turning point. With the stock sitting roughly 8% above its 52-week low of €32.84 from mid-May, the move has given bulls a foothold — but the journey back to last summer's peak of €49.86 still requires a near-29% advance.
The rally comes despite a backdrop that has tested investor patience. Siemens Healthineers has slashed its full-year guidance twice in quick succession, now forecasting revenue growth of 4.5% to 5.0%, down from the earlier range of 5.0% to 6.0%. Adjusted earnings per share are also expected to land between €2.20 and €2.30, narrower than the previous target. CFO Jochen Schmitz has pointed to inflation in memory chips, raw materials, and logistics costs as the primary culprits, with geopolitical tensions in the Middle East adding further pressure.
The picture is sharply divided beneath the surface. Imaging and Precision Therapy continue to deliver solid results, but the diagnostics division — a business Siemens Healthineers has been weighing spinning off — remains the sore spot. Currency-adjusted declines in China have been particularly acute, and management is keeping "all options" open regarding the unit's future, though no formal timeline for a separation has been set.
Analyst sentiment reflects the uncertainty. Deutsche Bank rates the stock a "Hold," while RBC recently trimmed its price target to €45 but maintained an "Outperform" rating. The divergence captures the central debate: is Siemens Healthineers fairly valued where it sits, or does the sell-off — roughly 26% over the past twelve months — present a buying opportunity?
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
The technical picture offers some encouragement. The relative strength index sits at 57.4, neutral territory that leaves room for further upside without signaling overbought conditions. The stock has gained 3.86% over the past 30 days, suggesting an initial base may be forming. But the 200-day moving average at €39.70 remains more than 10% above the current price, a reminder that the medium-term downtrend is far from broken.
All eyes now turn to the third-quarter results due in the coming days. Consensus among 18 analysts points to full-year earnings per share of €2.22, up from €1.91 last year, with revenue expected at €23.67 billion versus €23.38 billion. The quarterly numbers tell a more cautious story: eight analysts forecast EPS of €0.53, compared with €0.49 a year ago, while seven see revenue dipping 0.23% to €5.65 billion. The gap between the subdued quarterly outlook and the more optimistic full-year projections implies that any improvement is expected to materialize later in the fiscal year.
For the stock to sustain its recovery, the diagnostics division will need to show signs of stabilization. If the China headwinds persist and cost pressures remain elevated, uncertainty will likely keep the shares range-bound between the 52-week low and the 50-day moving average of €34.65. A break below that level would test the recent lows. Conversely, if the Q3 report confirms the full-year guidance and diagnostics shows even modest improvement, the path toward the 200-day line could reopen.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
The next few days will determine whether this is a technical bounce within a longer downtrend — or the beginning of something more durable.
Ad
Siemens Healthineers Stock: New Analysis - 27 July
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
